AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results. The drugmaker said ...

In Study 22, the tremelimumab/Imfinzi regimen achieved a median overall survival (OS) of 18.7 months, a finding which AZ’s head of oncology R&D José Baselga said could “change the treatment ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, supporting the indication of a single ...

Tremelimumab was also granted orphan designation in the EU in HCC in 2020. “HIMALAYA is the first Phase III trial to add a novel single priming dose of an anti-CTLA4 antibody to another ...

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard ...

First-line treatment with durvalumab plus tremelimumab and chemotherapy appeared effective for patients with metastatic non-small cell lung cancer, according to randomized phase 3 study results.

Patients (n = 1,013) with EGFR/ALK wild-type mNSCLC were randomly assigned (1:1:1) to tremelimumab 75 mg plus durvalumab 1,500 mg and platinum-based chemotherapy for up to four 21-day cycles, followed ...

A single priming dose of tremelimumab plus IMFINZI every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also showed no increase in severe liver toxicity and fewer ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI ® (durvalumab) demonstrated a ...

Please provide your email address to receive an email when new articles are posted on . Durvalumab plus tremelimumab significantly extended OS compared with sorafenib among patients with advanced ...

The approval was based on data from a phase 3 POSEIDON study. The Food and Drug Administration (FDA) has approved Imjudo (tremelimumab-actl) in combination with Imfinzi (durvalumab) and platinum ...